Smarter RNA molecules

Transforming cancer treatment with
smart RNA therapeutics

Our purpose
The field of RNA therapeutics has made extraordinary strides since the COVID-19 pandemic, which served as a catalyst for the rapid advancement, acceptance, and application of RNA technology in medicine. Once considered a novel approach, RNA technology is now emerging as a powerful tool in the fight against cancer.

Many cancer patients currently face limited treatment options due to the lack of targetable markers, leading to poor outcomes, reduced progression-free intervals, and lower overall survival rates.

Our vision is to revolutionize cancer treatment by developing smart RNA molecules capable of precisely distinguishing cancer cells based on the absence of specific genetic markers, rather than their presence. This innovative approach aims to establish a completely new set of therapeutic targets, offering hope for improved outcomes in patients with few existing options.

Ultimately, patients are at the center of our efforts to combat these cancers and our goal is to equip doctors with the tools they need to provide exceptional care.
Our Science
RXcel is transforming cancer treatment by targeting the absence of certain genetic markers instead of the usual focus on overexpressed ones. For instance, some cancers, like pancreatic cancer and glioblastoma, grow unchecked due to the loss of protective genes like CDKN2A. RXcel's smart RNA molecules can detect these missing genes and activate a treatment response only when they are absent. 

By analyzing large public datasets, RXcel identifies key targets, refines the RNA to include therapeutic components, and ensures effective delivery with advanced systems. Collaborating with experts and manufacturers, RXcel is paving the way for more precise and innovative cancer therapies.
Collaboration
To further strengthen our vision and operations, we are in the process of establishing a leading advisory board composed of scientific, medical, and legal experts. We are proud to have already secured two distinguished advisors: an European leading RNA expert and a global Therapeutic Area expert in glioblastoma, both of whom bring invaluable expertise to RXcel. This growing network of advisors and consultants will provide strategic guidance, industry insights, and regulatory expertise, ensuring that RXcel is well-positioned for success in the rapidly evolving biotech landscape.

Meet the RXcel team

Simon Bürssner, MSc

Co-founder

Biologist (M.Sc.) with expertise in lipid nano carriers and RNA therapeutics, pharma consultant with a strong industry network

Michal Kloc, PhD

Co-founder

Physicist and data scientist with a PhD in theoretical and computational physics Extensive experience in computational cancer biology

About RXcel
At RXcel, we stay at the forefront of scientific advancements. We have developed a groundbreaking approach using RNA therapeutics to specifically and selectively target cancer cells. 

Our multinational team combines deep scientific expertise and extensive industry experience to drive innovation in RNA therapeutics and oncology. With backgrounds in biology, physics, and pharmaceutical industry, we bring a multidisciplinary approach to tackling complex challenges. We founded our company in Basel, Switzerland, a global biotech hub, and have since expanded with an operational arm in Freiburg, Germany, where one of our founders is based. This strategic presence strengthens our ability to collaborate across borders and access key scientific and business networks.

Join us on our journey towards a brighter future!